HK1212207A1 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith - Google Patents

Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Info

Publication number
HK1212207A1
HK1212207A1 HK16100005.5A HK16100005A HK1212207A1 HK 1212207 A1 HK1212207 A1 HK 1212207A1 HK 16100005 A HK16100005 A HK 16100005A HK 1212207 A1 HK1212207 A1 HK 1212207A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
treatment therewith
pyrrolopyrimidine compounds
substituted pyrrolopyrimidine
Prior art date
Application number
HK16100005.5A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew Antony Calabrese
Brandon David Jeffy
Dale Robinson
Dan Zhu
Dehua Huang
Jan Elsner
John Frederick Boylan
Lida Tehrani
Mark A Nagy
Raj Kumar Raheja
Paul Erdman
Rama K Narla
Roy L Harris
Tam Minh Tran
Jennifer R Riggs
Yuhong Ning
Shuichan Xu
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50031611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of HK1212207A1 publication Critical patent/HK1212207A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16100005.5A 2013-01-16 2016-01-04 Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith HK1212207A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753259P 2013-01-16 2013-01-16
PCT/US2014/011612 WO2014113429A2 (fr) 2013-01-16 2014-01-15 Composés de type pyrrolopyrimidine substituée, compositions en contenant et méthodes de traitement faisant appel à eux

Publications (1)

Publication Number Publication Date
HK1212207A1 true HK1212207A1 (en) 2016-06-10

Family

ID=50031611

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100005.5A HK1212207A1 (en) 2013-01-16 2016-01-04 Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Country Status (24)

Country Link
US (3) US9428509B2 (fr)
EP (2) EP3202403A1 (fr)
JP (1) JP2016505041A (fr)
KR (1) KR20150108389A (fr)
CN (1) CN105188704B (fr)
AR (1) AR094494A1 (fr)
AU (1) AU2014207641A1 (fr)
BR (1) BR112015016997A2 (fr)
CA (1) CA2897985A1 (fr)
CL (1) CL2015001990A1 (fr)
EA (1) EA201591327A1 (fr)
EC (1) ECSP15030799A (fr)
ES (1) ES2638179T3 (fr)
HK (1) HK1212207A1 (fr)
IL (1) IL239901A0 (fr)
MX (1) MX2015009209A (fr)
NI (1) NI201500094A (fr)
NZ (1) NZ630467A (fr)
PE (1) PE20151995A1 (fr)
PH (1) PH12015501576A1 (fr)
SG (1) SG11201505446WA (fr)
TW (1) TW201441227A (fr)
WO (1) WO2014113429A2 (fr)
ZA (1) ZA201505011B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) * 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US10611765B2 (en) 2014-11-06 2020-04-07 Ohio State Innovation Foundation Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors
WO2016130920A2 (fr) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
CN105906630B (zh) * 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
SG11201710604SA (en) * 2015-06-22 2018-01-30 Ono Pharmaceutical Co Brk inhibitory compound
WO2017011720A1 (fr) * 2015-07-16 2017-01-19 Signal Pharmaceuticals, Llc 4-((4(cyclopentyloxy)-5-méthylbenzo[d]oxazol-6-yl)-17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-méthoxy-n-méthylbenzamide sous forme solide, compositions correspondantes et procédés d'utilisation correspondants
EP3336090B1 (fr) * 2015-08-13 2020-07-22 Beijing Hanmi Pharmaceutical Co., Ltd. Inhibiteur de l'irak4 et son utilisation
CA3001903A1 (fr) 2015-10-13 2017-04-20 The Scripps Research Institute Ciblage therapeutique de la caseine kinase 1.delta. dans le cancer du sein
WO2017079759A1 (fr) 2015-11-06 2017-05-11 Samumed, Llc 2-(3h-indazol-3-yl)-1h-imidazo[4,5-c]pyridines et leurs utilisations anti-inflammatoires
CN105646496B (zh) * 2016-01-20 2018-07-20 华侨大学 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用
MX2018014871A (es) 2016-06-01 2019-11-05 Samumed Llc Proceso de preparacion de n-(5-(3-(7-(3-fluorofenil)-3h-imidazo[4, 5-c]piridin-2-il)-1h-indazol-5-il)piridin-3-il)-3-metilbutanamida .
CN108727400B (zh) * 2017-05-24 2021-07-09 四川晶华生物科技有限公司 一种治疗肿瘤的化合物
MX2020004981A (es) * 2017-10-27 2020-08-24 Bayer Ag Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
KR20200104336A (ko) * 2017-12-28 2020-09-03 재단법인 생물기술개발중심 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물
KR102577242B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
SI3733673T1 (sl) 2017-12-28 2022-09-30 Daewoong Pharmaceutical Co., Ltd. Oksi-fluoropiperidinski derivat kot kinazni inhibitor
AU2019270089B2 (en) 2018-05-15 2022-11-10 University Of Tennessee Research Foundation Compounds for treatment of triple negative breast cancer and ovarian cancer
WO2020150552A2 (fr) 2019-01-17 2020-07-23 Samumed, Llc Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk
AU2022265032A1 (en) * 2021-04-30 2023-11-16 Wigen Biomedicine Technology (shanghai) Co., Ltd. Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof
US20240207271A1 (en) * 2021-05-03 2024-06-27 Jbklab Co.,Ltd. Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
WO2023064361A1 (fr) * 2021-10-12 2023-04-20 Biosplice Therapeutics, Inc. 7h-pyrrolo[2, 3-d]pyrimidines et leur préparation et leurs utilisations

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (fr) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
US6093728A (en) 1997-09-26 2000-07-25 Asta Medica Aktiengesellschaft Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
EP1347982B1 (fr) 2000-12-12 2005-11-16 Neurogen Corporation Spiro isobenzofuran-1,4'-piperidine]-3-ones et 3h-spiroisobenzofuran-1,4'-piperidines
WO2002076954A1 (fr) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Composes utiles en tant qu'inhibiteurs de kinase pour le traitement de maladies hyperproliferantes
JP3876254B2 (ja) 2001-09-04 2007-01-31 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なジヒドロプテリジノン、その製造方法及びその医薬組成物としての使用
EP1438048A1 (fr) 2001-10-18 2004-07-21 Boehringer Ingelheim Pharmaceuticals Inc. Composes d'uree benzo fusionnes 1,4-disubstitues utilises comme inhibiteurs des cytokines
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
EP1501850A2 (fr) 2002-05-06 2005-02-02 Genelabs Technologies, Inc. Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
US20040204420A1 (en) 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
CA2502429A1 (fr) 2002-10-31 2004-05-21 Amgen Inc. Agents anti-inflammatoires
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2517020C (fr) 2003-02-26 2012-06-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, prodede de production et utilisation de ces dernieres comme medicaments
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
AU2004232308A1 (en) 2003-04-23 2004-11-04 Wyeth Holdings Corporation PEG-wortmannin conjugates
PL3521297T3 (pl) 2003-05-30 2022-04-04 Gilead Pharmasset Llc Zmodyfikowane fluorowane analogi nukleozydów
CA2529196A1 (fr) 2003-06-26 2005-02-17 Merck & Co., Inc. Antagonistes du recepteur du cgrp de
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (fr) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. Procédé permettant de produire un dérivé de 2-arylpurine
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1796467A4 (fr) 2004-09-24 2009-07-01 Janssen Pharmaceutica Nv Inhibiteurs imidazo{4,5-b}pyrazinone de proteines kinases
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
WO2006050076A1 (fr) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
ES2308731T3 (es) 2005-02-16 2008-12-01 Astrazeneca Ab Compuestos quimicos.
WO2006091737A1 (fr) 2005-02-24 2006-08-31 Kemia, Inc. Modulateurs de l'activite de gsk-3
EP1874772A1 (fr) 2005-04-05 2008-01-09 Pharmacopeia, Inc. Derives de purine et d'imidazopyridine en vue d'une immunosuppression
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
EP2995619B1 (fr) 2006-08-02 2019-09-25 Cytokinetics, Inc. Certaines entites chimiques comprenant imidazopyrimines, compositions et procedes
EP2364702A3 (fr) 2006-09-05 2012-01-25 Emory University Inhibiteurs de kinase pour la prévention ou le traitement d'une infection
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
ZA200902382B (en) 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
US20090258096A1 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
JP2011518219A (ja) * 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010068483A2 (fr) 2008-11-25 2010-06-17 University Of Rochester Inhibiteurs de mlk et procédés d'utilisation
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
WO2011097333A1 (fr) 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification d'une mutation lkb1 comme biomarqueur de prédiction de sensibilité à des inhibiteurs de kinase tor
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
US20130158023A1 (en) 2011-08-03 2013-06-20 Signal Pharmaceuticals, Llc Identification of gene expression as a predictive biomarker for lkb1 status
UA110259C2 (uk) 2011-09-22 2015-12-10 Пфайзер Інк. Похідні піролопіримідину і пурину
EP3659599B1 (fr) 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one pour l'utilisation dans le traitement du glioblastome multiforme
CA3125862A1 (fr) 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Compositions pharmaceutiques de 7-(6-(2-hydroxypropan-2-yl)pyridine-3-yl)-1-((trans)-4-methoxycyclohexyle)-3,4-dihydropyrazino [2,3-b]pyrazine-2(1h)-one, forme solide connexe et methodes d'utilisation
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
TWI664968B (zh) 2012-03-15 2019-07-11 標誌製藥公司 使用tor激酶抑制劑之癌症治療
NZ628416A (en) 2012-03-15 2016-04-29 Signal Pharm Llc Treatment of cancer with tor kinase inhibitors
BR112014022700A2 (pt) 2012-03-15 2020-06-30 Signal Pharmaceuticals, Llc uso de uma quantidade eficaz de um inibidor da quinase tor, método para melhorar o critério do grupo de trabalho 2 do antígeno prostático específico (psawg2), método para a inibição da fosforilação de s6rp, 4e-bp1 e/ou de akt, método para a inibição da atividade da proteína quinase dependente do dna (dna-pk), método para a medição da inibição da fosforilação de s6rp, 4e-bp1 ou akt, método para a medição da inibição da fosforilação de dna-pk s2056 e kit
ES2618007T3 (es) * 2012-08-06 2017-06-20 Acea Biosciences, Inc. Nuevos compuestos de pirrolopirimidina como inhibidores de proteína cinasas
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013202768B2 (en) 2012-10-18 2015-11-05 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos

Also Published As

Publication number Publication date
EP2945636A2 (fr) 2015-11-25
CN105188704B (zh) 2017-09-19
SG11201505446WA (en) 2015-08-28
US20160324861A1 (en) 2016-11-10
KR20150108389A (ko) 2015-09-25
NI201500094A (es) 2015-09-21
US9346812B2 (en) 2016-05-24
ES2638179T3 (es) 2017-10-19
AR094494A1 (es) 2015-08-05
JP2016505041A (ja) 2016-02-18
PE20151995A1 (es) 2016-01-13
US20140200207A1 (en) 2014-07-17
US9428509B2 (en) 2016-08-30
ECSP15030799A (es) 2015-11-30
WO2014113429A3 (fr) 2014-10-09
EA201591327A1 (ru) 2015-12-30
TW201441227A (zh) 2014-11-01
WO2014113429A2 (fr) 2014-07-24
NZ630467A (en) 2017-02-24
MX2015009209A (es) 2016-03-17
BR112015016997A2 (pt) 2017-07-11
EP3202403A1 (fr) 2017-08-09
CN105188704A (zh) 2015-12-23
CA2897985A1 (fr) 2014-07-24
US20140200206A1 (en) 2014-07-17
CL2015001990A1 (es) 2016-01-22
EP2945636B1 (fr) 2017-06-28
IL239901A0 (en) 2015-08-31
AU2014207641A1 (en) 2015-08-06
PH12015501576A1 (en) 2016-02-01
ZA201505011B (en) 2016-11-30
US9795607B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
IL246252A0 (en) Diaminopyrimidyl derivative compounds, their compositions and methods of treatment
IL277069B (en) Modified aminopurine compounds, their compositions and methods of treatment with them
IL273090B (en) Methods and preparations for the treatment of cancer
IL245184B (en) Prostacyclin compounds, preparations and methods of using them
EP2986140A4 (fr) Compositions, procédés et trousses pour le traitement d'animaux domestiques
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
GB201320723D0 (en) Composition and methods of treatment
IL244066A0 (en) Triazolopyridine compounds, preparations and methods for their use
SG11201510594YA (en) Mixtures of compounds, their preparation, and uses
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
SG11201505220VA (en) Prevention & treatment of neuropathy
EP2967055A4 (fr) Compositions biocides, procédés de fabrication et procédés d'utilisation
EP3089745A4 (fr) Composés, compositions et méthodes de traitement de cancers
EP2800568A4 (fr) Compositions, procédés d'utilisation et procédés de traitement
HK1217715A1 (zh) 治療中風的組合物及方法
EP2994156A4 (fr) Composés, compositions et procédés permettant le traitement des maladies par inhibition de l'activité de tgf-